Literature DB >> 27663909

Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards-a retrospective study.

Noa Eliakim-Raz1, Roi Babaoff2, Dafna Yahav3, Shirly Yanai4, Hila Shaked3, Jihad Bishara3.   

Abstract

BACKGROUND: The clinical characteristics of internal medicine ward (IMW) patients with candidemia are unclear. The aim of this study was to define the clinical characteristics of candidemic IMW patients and to study the incidence, species distribution, and outcomes of these patients compared to surgical and intensive care unit (ICU) candidemic patients.
METHODS: A retrospective cohort of candidemic patients in IMWs, general surgery wards, and an ICU at Beilinson Hospital during the period 2007-2014 was analyzed.
RESULTS: A total of 118 patients with candidemia were identified in six IMWs, two general surgery wards, and one ICU in the hospital. Candida albicans was the leading causative agent (41.1%). Higher proportions of Candida parapsilosis and Candida tropicalis isolates were observed in the IMW patients. IMW patients were significantly older, with poorer functional capacity, and had more frequently been exposed to antibiotic therapy within 90 days, in particular β-lactam-β-lactamase inhibitor combinations and cephalosporins. At onset of candidemia, a significantly lower number of IMW patients were mechanically ventilated (p<0.01); these patients did not have central line catheters comparable to ICU and surgical patients (p<0.001). They were less likely to receive adequate antifungal therapy within 48h, and this was the only significant predictor of survival in these patients (p=0.028): hazard ratio 3.7 (95% confidence interval 1.14-12.5) for therapy delayed to >48h.
CONCLUSIONS: IMW candidemic patients account for a substantial proportion of candidemia cases and have unique characteristics and high mortality rates.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Candida species; Candidemia; Internal medicine ward

Mesh:

Substances:

Year:  2016        PMID: 27663909     DOI: 10.1016/j.ijid.2016.09.018

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  13 in total

Review 1.  What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.

Authors:  Matteo Bassetti; Elda Righi; Philippe Montravers; Oliver A Cornely
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

2.  Production and Isolation of the Candida Species Biofilm Extracellular Matrix.

Authors:  Marienella Hereidia; David Andes
Journal:  Methods Mol Biol       Date:  2022

3.  [Identification and susceptibility profile of Candida species isolated from hemocultures in hospitals in ParaguayIdentificação e perfil de sensibilidade de Candida spp. isoladas de hemoculturas em hospitais no Paraguai].

Authors:  Gustavo Aguilar; Patricia Araujo; Graciela Lird; Sonia Insaurralde; Aníbal Kawabata; Edelira Ayala; Juan Irala; Rocío Argüello
Journal:  Rev Panam Salud Publica       Date:  2020-09-23

4.  Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients.

Authors:  Antonella Torosantucci; Mario Tumbarello; Carla Bromuro; Paola Chiani; Brunella Posteraro; Maurizio Sanguinetti; Roberto Cauda; Antonio Cassone
Journal:  Sci Rep       Date:  2017-06-02       Impact factor: 4.379

5.  A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes.

Authors:  Lourdes Rodriguez; Beatriz Bustamante; Luz Huaroto; Cecilia Agurto; Ricardo Illescas; Rafael Ramirez; Alberto Diaz; Jose Hidalgo
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

6.  Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait.

Authors:  Ziauddin Khan; Suhail Ahmad; Noura Al-Sweih; Eiman Mokaddas; Khalifa Al-Banwan; Wadha Alfouzan; Inaam Al-Obaid; Khaled Al-Obaid; Mohammad Asadzadeh; Ahlam Jeragh; Leena Joseph; Soumya Varghese; Sandhya Vayalil; Omar Al-Musallam
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

Review 7.  Current Aspects in the Biology, Pathogeny, and Treatment of Candida krusei, a Neglected Fungal Pathogen.

Authors:  Manuela Gómez-Gaviria; Héctor M Mora-Montes
Journal:  Infect Drug Resist       Date:  2020-06-10       Impact factor: 4.003

8.  The Epidemiology and Susceptibility of Candidemia in Jerusalem, Israel.

Authors:  Sarah Israel; Sharon Amit; Ariel Israel; Ayalah Livneh; Ran Nir-Paz; Maya Korem
Journal:  Front Cell Infect Microbiol       Date:  2019-10-11       Impact factor: 5.293

Review 9.  The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future.

Authors:  Gloria Hoi Wan Tso; Jose Antonio Reales-Calderon; Norman Pavelka
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

10.  A 5-Year Review of Invasive Fungal Infection at an Academic Medical Center.

Authors:  Yaling Li; Yali Gao; Xueli Niu; Yutong Wu; Yimei Du; Ying Yang; Ruiqun Qi; Hongduo Chen; Xinghua Gao; Bing Song; Xiuhao Guan
Journal:  Front Cell Infect Microbiol       Date:  2020-10-22       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.